Sofosbuvir-Velpatasvir for Treating Chronic Hepatitis C (TA430)

Technology Appraisal Guidance No. 430

Source: National Institute for Health and Care Excellence

1. Guidance

1.1 Sofosbuvir–velpatasvir is recommended as an option for treating chronic hepatitis C in adults, as specified in table 1, only if the company provides the drug with the discount agreed in the simple discount agreement.

Table 1 Sofosbuvir-velpatasvir for treating chronic hepatitis C in adults

HCV
genotype
Liver disease stage Treatment Recommendation according to treatment history
Untreated Treated
1 With or without compensated cirrhosis Sofosbuvir-velpatasvir Recommended
2 Without cirrhosis Sofosbuvir-velpatasvir Recommended only for people who cannot tolerate interferon or it is not suitable for them Recommended
Compensated cirrhosis Sofosbuvir-velpatasvir Recommended
3 Without cirrhosis Sofosbuvir-velpatasvir Recommended
Compensated cirrhosis Sofosbuvir-velpatasvir (with or without ribavirin) Recommended
4 With or without compensated cirrhosis Sofosbuvir-velpatasvir Recommended
5 With or without compensated cirrhosis Sofosbuvir-velpatasvir Recommended
6 With or without compensated cirrhosis Sofosbuvir-velpatasvir Recommended
1-6 Decompensated cirrhosis Sofosbuvir-velpatasvir (with ribavirin) Recommended
Abbreviation: HCV, hepatitis C virus

Treated - the person's hepatitis C has not adequately responded to interferon-based treatment.

1.2 It is recommended that the decision to treat and prescribing decisions are made by multidisciplinary teams in the operational delivery networks put in place by NHS England, to prioritise treatment for people with the highest unmet clinical need.

1.3 This guidance is not intended to affect the position of patients whose treatment with sofosbuvir–velpatasvir was started within the NHS before this guidance was published. Treatment of those patients may continue without change to whatever funding arrangements were in place for them before this guidance was published until they and their NHS clinician consider it appropriate to stop.


The guidance shown above constitutes Section 1 of the full document. A copy of the full document and a summary of the evidence is available on the Internet at www.nice.org.uk/guidance/ta430

This guidance represents the view of the Institute which was arrived at after careful consideration of the available evidence. Health professionals are expected to fully take it into account when exercising their clinical judgement. This guidance does not, however, override the individual responsibility of health professionals to make appropriate decisions in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

© Copyright National Institute for Health and Care Excellence. All rights reserved. This material may be freely reproduced for educational and not for profit purposes within the NHS. No reproduction by or for commercial organisations is permitted without the express written permission of the Institute.

Enquiries concerning the guidance should be addressed to: National Institute for Health and Care Excellence, MidCity Place, 71 High Holborn, London WC1V 6NA. email: nice@nice.org.uk

Sofosbuvir-velpatasvir for treating chronic hepatitis C

Issue Date: January 2017


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases